Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38:2125–35.

Article  CAS  PubMed  Google Scholar 

Sonbol MB, Halfdanarson TR, Hilal T. Assessment of therapy-related myeloid neoplasms in patients with neuroendocrine tumors after peptide receptor radionuclide therapy: a systematic review. JAMA Oncol. 2020;6:1086–92.

Article  PubMed  Google Scholar 

Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42:5–19.

Article  CAS  PubMed  Google Scholar 

Sabet A, Ezziddin K, Pape U-F, Ahmadzadehfar H, Mayer K, Pöppel T, et al. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2013;54:1857–61.

Article  CAS  PubMed  Google Scholar 

Sjögreen Gleisner K, Chouin N, Gabina PM, Cicone F, Gnesin S, Stokke C, et al. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. 2022 [cited 2022 Apr 6]; Available from: https://doi.org/10.1007/s00259-022-05727-7.

Hagmarker L, Svensson J, Rydén T, van Essen M, Sundlöv A, Gleisner KS, et al. Bone marrow absorbed doses and correlations with hematologic response during 177Lu-DOTATATE treatments are influenced by image-based dosimetry method and presence of skeletal metastases. J Nucl Med. 2019;60:1406–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garske-Román U, Sandström M, Fröss Baron K, Lundin L, Hellman P, Welin S, et al. Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. Eur J Nucl Med Mol Imaging. 2018;45:970–88.

Article  PubMed  PubMed Central  Google Scholar 

Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0, Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2009;36:1138.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lassmann M, Hänscheid H, Chiesa C, Hindorf C, Flux G, Luster M. EANM dosimetry committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging. 2008;35:1405.

Article  PubMed  Google Scholar 

Page ER. Impact of 3D image based dosimetry on treatment planning in Peptide Receptor Radionuclide Therapy (PRRT). 381.

Kwekkeboom DJ, Willem H. Bakker, Peter P. M. Kooij, Mark W. Konijnenberg, Ananth Srinivasan, Jack L. Erion, et al. [177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med. 2001;1319–25.

Wehrmann C, Senftleben S, Zachert C, Müller D, Baum RP. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC | cancer biotherapy and radiopharmaceuticals. Cancer Biotherapy & Radiopharmaceuticals. 2007 [cited 2022 Nov 22]; https://doi.org/10.1089/cbr.2006.325

Jackson PA, Beauregard J-M, Hofman MS, Kron T, Hogg A, Hicks RJ. An automated voxelized dosimetry tool for radionuclide therapy based on serial quantitative SPECT/CT imaging. Med Phys. 2013;40:112503.

Article  PubMed  Google Scholar 

Sandström M, Garske-Román U, Granberg D, Johansson S, Widström C, Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 2013;54:33–41.

Article  PubMed  Google Scholar 

Denoyer D, Lobachevsky P, Jackson P, Thompson M, Martin OA, Hicks RJ. Analysis of 177Lu-DOTA-octreotate therapy-induced DNA damage in peripheral blood lymphocytes of patients with neuroendocrine tumors. J Nucl Med. 2015;56:505–11.

Article  CAS  PubMed  Google Scholar 

Bergsma H, Konijnenberg MW, Kam BLR, Teunissen JJM, Kooij PP, de Herder WW, et al. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course. Eur J Nucl Med Mol Imaging. 2016;43:453–63.

Article  CAS  PubMed  Google Scholar 

Svensson J, Rydén T, Hagmarker L, Hemmingsson J, Wängberg B, Bernhardt P. A novel planar image-based method for bone marrow dosimetry in 177Lu-DOTATATE treatment correlates with haematological toxicity. EJNMMI Phys. 2016 [cited 2017 Jan 25];3. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5031567/

Del Prete M, Buteau F-A, Beauregard J-M. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study. Eur J Nucl Med Mol Imaging. 2017;44:1490–500.

Article  PubMed  Google Scholar 

Gosewisch A, Delker A, Tattenberg S, Ilhan H, Todica A, Brosch J, et al. Patient-specific image-based bone marrow dosimetry in Lu-177-[DOTA0, Tyr3]-Octreotate and Lu-177-DKFZ-PSMA-617 therapy: investigation of a new hybrid image approach. EJNMMI Res. 2018;8:76.

Article  PubMed  PubMed Central  Google Scholar 

Del Prete M, Buteau F-A, Arsenault F, Saighi N, Bouchard L-O, Beaulieu A, et al. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging. 2019;46:728–42.

Article  PubMed  Google Scholar 

Santoro L, Mora-Ramirez E, Trauchessec D, Chouaf S, Eustache P, Pouget J-P, et al. Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [177Lu-[DOTA0, Tyr3]-octreotate. EJNMMI Res. 2018;8:103.

Article  PubMed  PubMed Central  Google Scholar 

Marin G, Vanderlinden B, Karfis I, Guiot T, Wimana Z, Reynaert N, et al. A dosimetry procedure for organs-at-risk in 177Lu peptide receptor radionuclide therapy of patients with neuroendocrine tumours. Phys Med. 2018;56:41–9.

Article  PubMed  Google Scholar 

Thakral P, Sen I, Pant V, Gupta SK, Dureja S, Kumari J, et al. Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM). Br J Radiol. 2018;91:20170172.

Article  PubMed  PubMed Central  Google Scholar 

Chicheportiche A, Artoul F, Schwartz A, Grozinsky-Glasberg S, Meirovitz A, Gross DJ, et al. Reducing the number of CTs performed to monitor personalized dosimetry during peptide receptor radionuclide therapy (PRRT). EJNMMI Phys. 2018;5:10.

Article  PubMed  PubMed Central  Google Scholar 

Hallqvist A, Svensson J, Hagmarker L, Marin I, Rydén T, Beauregard J-M, et al. Optimizing the Schedule of PARP Inhibitors in Combination with 177Lu-DOTATATE: a dosimetry rationale. Biomedicines. 2021;9:1570.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carter LM, Ramos JCO, Kesner AL. Personalized dosimetry of 177Lu-DOTATATE: a comparison of organ- and voxel-level approaches using open-access images. Biomed Phys Eng Express. 2021;7:057002.

Article  Google Scholar 

Vergnaud L, Giraudet A-L, Moreau A, Salvadori J, Imperiale A, Baudier T, et al. Patient-specific dosimetry adapted to variable number of SPECT/CT time-points per cycle for 177Lu-DOTATAE therapy. EJNMMI Phys. 2022;9:37.

Article  PubMed  PubMed Central  Google Scholar 

Lambert M, Dierickx L, Brillouet S, Courbon F, Chatelut E. Comparison of two types of amino acid solutions on 177Lu-dotatate pharmacokinetics and pharmacodynamics in patients with metastatic gastroenteropancreatic neuroendocrine tumors. Curr Radiopharm. 2022;15:164–72.

Article  CAS  PubMed  Google Scholar 

Huizing DMV, Peters SMB, Versleijen MWJ, Martens E, Verheij M, Sinaasappel M, et al. A head-to-head comparison between two commercial software packages for hybrid dosimetry after peptide receptor radionuclide therapy. EJNMMI Phys. 2020;7:36.

Article  PubMed  PubMed Central  Google Scholar 

Ferrer L, Kraeber-Bodéré F, Bodet-Milin C, Rousseau C, Gouill SL, Wegener WA, et al. Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy. Cancer. 2010;116:1093–100.

Article  CAS  PubMed  Google Scholar 

Glass HI, de Garreta AC. The quantitative limitations of exponential curve fitting. Phys Med Biol. 1971;16:119.

Article  CAS  PubMed  Google Scholar 

Beykan, S et al. Patient-specific dosimetry of 177Lu-dotatate peptide receptor radionuclide therapy with high activities. Eur J Nucl Med Mol Imaging 2018;45(Suppl 1):S33 OP-081. 2018.

Hemmingsson J, Svensson J, Hallqvist A, Smits K, Johanson V, Bernhardt P. Specific Uptake in the Bone Marrow Causes High Absorbed Red Marrow Doses During [177Lu]Lu-DOTATATE Treatment. J Nucl Med [Internet]. 2023 [cited 2023 Sep 22]; Available from: https://jnm.snmjournals.org/content/early/2023/06/08/jnumed.123.265484

Lubberink M, Wilking H, Öst A, Ilan E, Sandström M, Andersson C, et al. In Vivo Instability of 177Lu-DOTATATE During Peptide Receptor Radionuclide Therapy. J Nucl Med. 2020;61:1337–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Walrand S, Jamar F. Renal and red marrow dosimetry in peptide receptor radionuclide therapy: 20 years of history and ahead. Int J Mol Sci. 2021;22:8326.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van Hagen PM, Krenning EP, Kwekkeboom DJ, Reubi JC, Anker-Lugtenburg PJ, Löwenberg B, et al. Somatostatin and the immune and haematopoetic system: a review. Eur J Clin Invest. 1994;24:91–9.

Article  PubMed  Google Scholar 

Derlin T, Bogdanova N, Ohlendorf F, Ramachandran D, Werner RA, Ross TL, et al. Assessment of γ-H2AX and 53BP1 foci in peripheral blood lymphocytes to predict subclinical hematotoxicity and response in somatostatin receptor-targeted radionuclide therapy for advanced gastroenteropancreatic neuroendocrine tumors. Cancers. 2021;13:1516.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eberlein U, Nowak C, Bluemel C, Buck AK, Werner RA, Scherthan H, et al. DNA damage in blood lymphocytes in patients after 177Lu peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2015;42:1739–49.

Article  CAS  PubMed  PubMed Central  Google Scholar